Dahlberg S T, Leppo J A
Department of Nuclear Medicine, University of Massachusetts Medical Center, Worcester 01655, USA.
J Nucl Cardiol. 1994 Mar-Apr;1(2 Pt 1):189-97. doi: 10.1007/BF02984091.
The myocardial deposition of radiolabeled perfusion agents permits the noninvasive assessment of regional coronary blood flow. The design of imaging protocols and the optimal interpretation of clinical perfusion studies are based on an understanding of the kinetics of blood-tissue exchange for these compounds. Thallium 201 and the technetium 99m-labeled compounds sestamibi, teboroxime, and tetrofosmin show differing myocardial extraction and retention. This review focuses on studies that used cell culture, isolated heart, and intact animal models that form the basis of our current understanding of the myocardial kinetics of these imaging agents.